CCMU
IONS icon

Cheyne Capital Management (UK)’s Ionis Pharmaceuticals IONS Stock Holding History

Cheyne Capital Management (UK)’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,891
Closed -$249K – 50
2017
Q2 		$249K Buy
+4,891
New +$228K 0.1% 43

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Cheyne Capital Management (UK)'s IONS Position: Q3 2017 in Review

Cheyne Capital Management (UK) sold out of Ionis Pharmaceuticals (IONS) in Q3 2017, closing a stake of 4,891 shares — an estimated $249K sold.

Cheyne Capital Management (UK) first reported a position in IONS in Q2 2017 and held it in 1 quarter. The position peaked at $249K in Q2 2017. 301 funds tracked by Wall St. Rank hold IONS as of Q3 2017.

  • Cheyne Capital Management (UK) reported no remaining Ionis Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Cheyne Capital Management (UK) sold 4,891 Ionis Pharmaceuticals shares in Q3 2017, an estimated $249K.
  • Cheyne Capital Management (UK) first reported a position in Ionis Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Cheyne Capital Management (UK)'s Ionis Pharmaceuticals position peaked at $249K in Q2 2017.
  • 301 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2017.

Based on Cheyne Capital Management (UK)'s 13F filing for Q3 2017, filed 7 Nov 2017.